Top Markets
Coin of the day
TME Pharma N.V. TME Pharma N.V.

TME Pharma N.V.

ALTME
Rank in Stocks #33659
TME Pharma N.V., a biopharmaceutical company in the clinical development stage... TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Share Price
$0.07591393
Last synced: 2026-08-14
Market Cap
$7.15M
Change (1 day)
3.90%
Change (1 year)
-41.05%
Country
DE
Trade TME Pharma N.V. (ALTME)

Category

Stock price history for TME Pharma N.V. (ALTME)
Highest end of day price: $0.07 on 2026-08-01

Lowest end of day price: $2.42K on 2016-09-01
Stock price history of TME Pharma N.V. from 2016 to 2026
Annual Stock Price Performance
Year Performance
2026 (TTM) 32.43%
2025 -15.09%
2024 -67.73%
2023 -81.54%
2022 -95.65%
2021 -45.73%
2020 27.62%
2019 -67.02%
2018 -81.06%
2017 -65.91%
2016 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE